Discovery & Development

At NMS, from the Discovery phase onwards our aim is to transform the way in which cancer is treated and contribute towards making cancer a more manageable disease. The company quest is therefore devoted to the understanding of cancer mechanisms instrumental in the definition of novel approaches to and treatment of this disease.
 
Our mission is to identify innovative agents suitable for clinical development in areas of unmet medical needs in Oncology.
 
The use of a conceptual approach to drug discovery in Oncology implies the designing of small molecule inhibitors of key proteins of proven relevance in tumour growth. To this concern, the company has gained considerable experience in the field of protein kinases, known to play a key role in the deregulated cell cycle progression and signal transduction of cancer cells.

Research and development

In this perspective, Oncology R&D is a fully integrated group in which the researchers involved in drug discovery and clinical development activities operate in close collaboration in a stimulating professional environment.

In particular, this teamwork makes it possible to speed up the process that aims at the discovery and development of new anticancer drugs with a significant impact on the treatment of cancer, increasing the likelihood of success in overcoming the disease.

The Discovery unit comprehends a fully integrated team of chemists and biologists. The group, comprising over 200 scientists, has gained importance through international teamwork and involvement of top ranking scientists in fields ranging from target validation to identification of clinical candidates.